H.C. Wainwright reiterates Buy rating on Gyre Therapeutics stock at $18
PositiveFinancial Markets

H.C. Wainwright has reaffirmed its Buy rating on Gyre Therapeutics, setting a target price of $18 for the stock. This endorsement reflects confidence in Gyre's potential for growth and success in the market, which is encouraging news for investors looking for promising opportunities in the biotech sector.
— Curated by the World Pulse Now AI Editorial System